Provided by Tiger Trade Technology Pte. Ltd.

Adaptive Biotechnologies Corp

25.89
-0.1000-0.38%
Volume:686.44K
Turnover:17.57M
Market Cap:4.14B
PE:-62.95
High:25.99
Open:25.63
Low:25.10
Close:25.99
52wk High:26.16
52wk Low:12.00
Shares:159.76M
Float Shares:125.00M
Volume Ratio:0.77
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4113
EPS(LYR):-0.3922
ROE:-38.76%
ROA:-4.12%
PB:28.94
PE(LYR):-66.02

Loading ...

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Jul 30

Adaptive Biotechnologies CSO Harlan S. Robins Reports Disposal of Common Shares Worth $10.77 Million

Reuters
·
Jul 24

Is Adaptive Biotechnologies (ADPT) Fully Valued As Its Zacks Upgrade Lifts Earnings Hopes?

Simply Wall St.
·
Jul 23

Earning Preview: Adaptive Biotechnologies Corp Q2 revenue is expected to increase by 33.37%, and institutional views are predominantly bullish

Earnings Agent
·
Jul 23

Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Disposes of 5,000 Shares for $115,000

Reuters
·
Jul 21

Adaptive Biotechnologies Chief People Officer Francis Lo Disposes of 105,762 Common Shares Worth $2.39 Million

Reuters
·
Jul 18

Adaptive Biotechnologies (ADPT) Stock Looks Reasonable On Cash Flow Yet Rich On Sales

Simply Wall St.
·
Jul 11

Adaptive Biotechnologies is Maintained at Equal-weight by Morgan Stanley

Dow Jones
·
Jul 10

Adaptive Biotechnologies price target raised to $20 from $18 at Morgan Stanley

TIPRANKS
·
Jul 09

U.S. Research Roundup-applied Materials, CME Group, NASDAQ

Reuters
·
Jul 09

Adaptive Biotech CSO Harlan S. Robins Disposes of USD 8.49 Million in Common Shares

Reuters
·
Jul 08

Does Russell Index Removal Reshape the Bull Case for Adaptive Biotechnologies (ADPT)?

Simply Wall St.
·
Jul 07

Adaptive Biotechnologies CCO Susan Bobulsky Sells 487 Shares Worth $10,714

Reuters
·
Jul 07

Adaptive Biotechnologies Chief Commercial Officer Imm Med Sharon Benzeno Sells 165,802 Shares for $3.73 Million

Reuters
·
Jul 01

Adaptive Biotechnologies Director Michelle Renee Griffin Disposes of 52,084 Common Shares Worth $1,051,855.12

Reuters
·
Jun 30

Adaptive Biotechnologies (ADPT) Plans A Business Split, Is The Valuation Already Full?

Simply Wall St.
·
Jun 29

Adaptive Biotechnologies is Maintained at Buy by Guggenheim

Dow Jones
·
Jun 29

Adaptive Biotechnologies price target raised to $22 from $21 at Guggenheim

TIPRANKS
·
Jun 29

Adaptive Biotechnologies Issues $345 Million Convertible Notes

MT Newswires Live
·
Jun 23

Adaptive Biotechnologies Corp - Issues $345 Mln in 0% Convertible Senior Notes Due 2031 - SEC Filing

THOMSON REUTERS
·
Jun 23